BCG-induced protection against Mycobacterium tuberculosis infection: Evidence, mechanisms, and implications for next-generation vaccines.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Hill, Philip C
Setiabudiawan, Todia Pediatama
Koeken, Valerie A C M
van Crevel, Reinout
MetadataShow full item record
AbstractThe tuberculosis (TB) vaccine Bacillus Calmette-Guérin (BCG) was introduced 100 years ago, but as it provides insufficient protection against TB disease, especially in adults, new vaccines are being developed and evaluated. The discovery that BCG protects humans from becoming infected with Mycobacterium tuberculosis (Mtb) and not just from progressing to TB disease provides justification for considering Mtb infection as an endpoint in vaccine trials. Such trials would require fewer participants than those with disease as an endpoint. In this review, we first define Mtb infection and disease phenotypes that can be used for mechanistic studies and/or endpoints for vaccine trials. Secondly, we review the evidence for BCG-induced protection against Mtb infection from observational and BCG re-vaccination studies, and discuss limitations and variation of this protection. Thirdly, we review possible underlying mechanisms for BCG efficacy against Mtb infection, including alternative T cell responses, antibody-mediated protection, and innate immune mechanisms, with a specific focus on BCG-induced trained immunity, which involves epigenetic and metabolic reprogramming of innate immune cells. Finally, we discuss the implications for further studies of BCG efficacy against Mtb infection, including for mechanistic research, and their relevance to the design and evaluation of new TB vaccines.
AffiliationCiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.
The following license files are associated with this item:
- Creative Commons
- Natural and trained innate immunity against Mycobacterium tuberculosis.
- Authors: Ferluga J, Yasmin H, Al-Ahdal MN, Bhakta S, Kishore U
- Issue date: 2020 May
- Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
- Authors: Gupta N, Garg S, Vedi S, Kunimoto DY, Kumar R, Agrawal B
- Issue date: 2018
- A multiple T cell epitope comprising DNA vaccine boosts the protective efficacy of Bacillus Calmette-Guérin (BCG) against Mycobacterium tuberculosis.
- Authors: Maurya SK, Aqdas M, Das DK, Singh S, Nadeem S, Kaur G, Agrewala JN
- Issue date: 2020 Sep 17
- "The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report.
- Authors: Boggiano C, Eichelberg K, Ramachandra L, Shea J, Ramakrishnan L, Behar S, Ernst JD, Porcelli SA, Maeurer M, Kornfeld H
- Issue date: 2017 Jun 14